Suven’s depression drug shows promise in phase 2a trial; stocks trade flat 1 min read Markets Suven’s depression drug shows promise in phase 2a trial; stocks trade flat Daily News Express September 18, 2024 Suven Life Sciences announced positive topline results from its Phase 2a proof-of-concept study for Ropanicant (SUVN-911), a...Read More
